Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600125092) titled 'Remimazolam versus dexmedetomidine on postoperative quality of recovery in frail elderly patients undergoing bronchoscopy: a randomized controlled trial' on May 21.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Shanghai Changhai Hospital
Condition:
Frailty
Intervention:
Remimazolam group:The initial dose of remimazolam was 0.1 mg/kg administered via infusion for 3 minutes, followed by maintenance infusion at a rate of 0.1-0.5 mg/kg/h.
The initial target plasma concentration of remifentanil was set at 2.5 ng/mL with a peak effect time of 3 minutes, and then adjusted within the ran...